Global

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments for underserved patient communities, with a primary focus on sickle cell disease (SCD). The company's flagship product, Oxbryta (voxelotor), is a first-in-class oral therapy that directly inhibits hemoglobin polymerization, the root cause of red blood cell sickling. GBT's pipeline includes next-generation hemoglobin S polymerization inhibitors and other therapies aimed at reducing the complications of SCD. In 2022, the company was acquired by Pfizer for approximately $5.4 billion to bolster Pfizer's rare disease and hematology portfolio. GBT continues to operate as a key part of Pfizer's efforts to transform the standard of care for patients with lifelong hematologic disorders.